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Abstract
Background: Antidepressants are heavily prescribed drugs and have been shown to affect inflammatory signals. We
examined whether these have anti-inflammatory properties in animal models of septic shock and allergic asthma. We also
analysed whether antidepressants act directly on peripheral cell types that participate in the inflammatory response in
these diseases.
Methods: The antidepressants desipramine and fluoxetine were compared in vivo to the glucocorticoid prednisolone,
an anti-inflammatory drug of reference. In a murine model of lipopolysaccharides (LPS)-induced septic shock, animals
received the drugs either before or after injection of LPS. Circulating levels of tumour necrosis factor (TNF)-α and
mortality rate were measured. In ovalbumin-sensitized rats, the effect of drug treatment on lung inflammation was
assessed by counting leukocytes in bronchoalveolar lavages. Bronchial hyperreactivity was measured using barometric
plethysmography. In vitro production of TNF-α and Regulated upon Activation, Normal T cell Expressed and presumably
Secreted (RANTES) from activated monocytes and lung epithelial cells, respectively, was analysed by immunoassays.
Reporter gene assays were used to measure the effect of antidepressants on the activity of nuclear factor-κB and
activator protein-1 which are involved in the control of TNF-α and RANTES expression.
Results: In the septic shock model, all three drugs given preventively markedly decreased circulating levels of TNF-α
and mortality (50% mortality in fluoxetine treated group, 30% in desipramine and prednisolone treated groups versus
90% in controls). In the curative trial, antidepressants had no statistically significant effect, while prednisolone still
decreased mortality (60% mortality versus 95% in controls). In ovalbumin-sensitized rats, the three drugs decreased lung
inflammation, albeit to different degrees. Prednisolone and fluoxetine reduced the number of macrophages, lymphocytes,
neutrophils and eosinophils, while desipramine diminished only the number of macrophages and lymphocytes. However,
antidepressants as opposed to prednisolone did not attenuate bronchial hyperreactivity. In vitro, desipramine and
fluoxetine dose-dependently inhibited the release of TNF-α from LPS-treated monocytes. In lung epithelial cells, these
compounds decreased TNF-α-induced RANTES expression as well as the activity of nuclear factor-κB and activator
protein-1.
Conclusion: Desipramine and fluoxetine reduce the inflammatory reaction in two animal models of human diseases.
These antidepressants act directly on relevant peripheral cell types to decrease expression of inflammatory mediators
probably by affecting their gene transcription. Clinical implications of these observations are discussed.
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Background
It was hypothesized more than 30 years ago that depres-
sion involves a deficiency in monoamine neurotransmis-
sion. Immune activation may be causally related to these
signaling disorders, as inflammatory cytokines have been
shown to alter monoamine turnover, decrease activity of
presynaptic serotoninergic neurons, and activate serot-
onin re-uptake from the synaptic cleft [1,2]. According to
this hypothesis, therapeutic effects of antidepressants
could be at least partly exerted by attenuating brain
expression or action of inflammatory cytokines [3,4]. In
this line, administration of the tricyclic antidepressant
desipramine in rats has been shown to result in a virtual
ablation of neuron-derived tumour necrosis factor (TNF)-
α [5,6]. Intracerebroventricular microinfusion of TNF-α
prevents the efficacy of desipramine while that of TNF-α
antibody mimics the therapeutic effect of the antidepres-
sant, providing further evidences that this cytokine plays a
key role in the pathogenesis of depression [7].
Interestingly, antidepressants are also able to decrease
peripheral inflammation. Chlomipramine, another tricy-
clic antidepressant, and fluoxetine, a specific inhibitor of
serotonin reuptake, reduce oedema induced by the injec-
tion of yeast suspension in the rat hind paw [8,9].
Recently, preventive treatment with bupropion-amfebuta-
mone, a noradrenalinedopamine reuptake inhibitor, was
shown to reduce TNF-α release and mortality in a murine
model of severe sepsis [10]. In these studies, the anti-
inflammatory effects of fluoxetine and bupropion
involved, at least partly, a central action.
Depression is a common illness with a 17% lifetime prev-
alence in the general population [11]. Of note, depressive
symptoms and disorders seem to be even more common
in asthma patients [12,13]. Lifetime rates of depressive
disorder of up to 41% have been reported in clinical sam-
ples of patients with asthma [14,15]. Thus, the aim of the
present study was to determine the effect of desipramine
and fluoxetine in two animal models of human inflam-
matory disorders, namely septic shock and allergic
asthma. In the septic shock model, antidepressants were
given either preventively or curatively. We report that
desipramine and fluoxetine have therapeutic effects and
counteract inflammation in these models. Our data fur-
ther indicate that these antidepressants can directly act on
relevant peripheral cell types to decrease expression of
inflammatory cytokines. Finally, we show that
desipramine and fluoxetine reduce the activity of the tran-
scription factors nuclear factor (NF)-κB and activator pro-
tein (AP)-1, which have been shown to control expression
of these cytokines [16,17].
Methods
Reagents
12-O-tetradecanoyl-phorbol-13-acetate (TPA), lipopoly-
saccharides (LPS; Escherichia coli serotype 0111:B4),
ovalbumin (OVA), aluminium hydroxide, metacholine,
prednisolone and desipramine were purchased from
Sigma. Fluoxetine was obtained from Tocris. Recom-
binant human TNF-α was purchased from BD Pharmin-
gen. For in vivo studies, antidepressants and prednisolone
were dissolved in saline. For in vitro studies, antidepres-
sants were initially dissolved in absolute ethanol at 10-2
M. Dilutions with medium were freshly made from origi-
nal stocks to a maximal concentration of 10-5 M as in pre-
vious studies ([18] and references therein). No toxic
effects of the drugs or solvents were observed at these dilu-
tions as checked by vital staining with trypan blue and lac-
tate dehydrogenase dosage in supernatants.
Cell culture
A549 human lung epithelial cells were maintained in
Ham's F12/Dulbecco's modified Eagle's medium contain-
ing 10 % heat-inactivated fœtal calf serum, 100 U/ml pen-
icillin, 100 mg/ml streptomycin and 2 mM glutamine.
Human monocytes were obtained by the following proce-
dure. Buffy coats were collected from the blood of healthy
donors. Blood mononuclear cells were isolated by den-
sity-gradient centrifugation through Ficoll-Hypaque
(Pharmacia), suspended in RPMI 1640 medium with 10
% heat-inactivated fœtal calf serum, and seeded in gelatin-
coated flasks. After incubation for 30 min at 37°C, serial
washes were performed to eliminate non-adherent cells
and adherent monocytes were detached with 10 mM
EDTA, resuspended in Iscove's modified Eagle's medium
containing 10 % heat-inactivated fœtal calf serum. The
day before transfection and/or stimulation, cells were
seeded in medium containing 5% charcoal/dextran
treated foetal calf serum.
Reporter plasmids
The AP-1-luciferase gene construct -517/+63 Coll Luc con-
sists of the luciferase gene driven by part of the colla-
genase promoter with its single AP-1 site (gift of Peter
Herrlich, Institute of Genetics, Karlsruhe, Germany). The
NF-κB-luciferase gene construct 3 × Igκ Cona Luc contains
three tandem repeats of the NF-κB response element from
the immunoglobulin κ chain linked to the conalbumin
minimal promoter and the luciferase gene (gift of Alain
Israël, Institut Pasteur, Paris, France). The pJ7-LacZ plas-
mid contains the SV40 early promoter linked to the β-
galactosidase gene.
RANTES and TNF-α immunoassays
Concentrations of Regulated upon Activation, Normal T
cell Expressed and presumably Secreted (RANTES) and
TNF-α were determined using quantitative sandwichRespiratory Research 2007, 8:35 http://respiratory-research.com/content/8/1/35
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enzyme immuno-assays as described by the manufacturer
(R&D Systems).
RANTES mRNA quantitation
Total cellular RNA was isolated with RNA PLUS (Quan-
tum Biotechnologies). Colorimetric RANTES mRNA
quantitation was performed using a Quantikine mRNA kit
(R&D Systems).
Transient transfection and reporter gene assays
100 000 cells per well were serum deprived overnight and
transfected with 60 ng of either 3 × Igκ Cona Luc or -517/
+63 Coll Luc and 25 ng of pJ7-LacZ. These were then stim-
ulated as indicated in the figure legends. Transfection,
luciferase and β-galactosidase assays were performed as
described previously [19]. Luciferase activity was divided
by β-galactosidase activity to normalise values for varia-
tions in transfection efficiency.
LPS-induced inflammation and endotoxic shock in mice
The effect of antidepressants in septic shock was studied
on 5-week-old BALB/c mice weighing 17–21 g (Elevage
Janvier). To study their protective effect, animals received
i.p. prednisolone, desipramine or fluoxetine at 5, 10 and
20 mg/kg or saline 30 min before injection of a lethal dose
of LPS (50 mg/kg, i.p.). Ninety min after receiving LPS,
blood was quickly collected from the trunk after decapita-
tion. The serum was then isolated by centrifugation after
clotting to determine the concentration of TNF-α. Addi-
tional groups of mice receiving saline or the test drugs at
20 mg/kg before LPS treatment were observed for survival.
To study the curative effect of antidepressants, animals
received a lethal infusion of LPS and were treated with
prednisolone (20 mg/kg, i.p), desipramine (20 mg/kg,
i.p.), fluoxetine (20 mg/kg, i.p.) or saline 4, 8, 12, 24, and
30 h later. Mortality was evaluated daily.
Measurement of bronchial responsiveness and 
inflammation in ovalbumin-sensitized rats
Ten-week-old Brown Norway rats were sensitized to oval-
bumin as follows: ovalbumin (1 mg/ml) was emulsified
with aluminium hydroxide (100 mg/ml) in saline prior to
i.p. injection of 1 ml per rat at day 1, 2, 3 and 16. From
day 22 to 29, prednisolone, desipramine, fluoxetine or
saline were i.p. administered at 10 mg/kg to rats 30 min
prior nebulisation with a 1% (w/v) ovalbumin solution
during 20 min. Unsensitized controls received i.p. injec-
tions of aluminium hydroxide alone. These were then
nebulised with saline from day 22 to 28 and challenged
with ovalbumin on day 29. Bronchial responsiveness to
metacholine (10 mg/ml nebulised during 2 min) was ana-
lysed by barometric plethysmography (Emka Technolo-
gies) on conscious unrestrained animals 24 h after the last
ovalbumin nebulisation. Enhanced pause (Penh), reflect-
ing the resistance to air flow, and hence airway obstruc-
tion, was measured. Rats were then anaesthetized with
pentobarbital and exsanguinated by catheterization of the
abdominal aorta to avoid contamination of bronchoalve-
olar lavages with red cells. The trachea was stripped and
rinsed in situ with PBS. Total number of cells in broncho-
alveolar lavages was immediately determined by counting
on Malassez chamber. The different cell types were distin-
guished and counted after cytocentrifugation, fixation and
May Grünwald Giemsa staining. These experimentations
have been carried out in accordance with the Declaration
of Helsinki and with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the
US National Institutes of Health. Our laboratory practice
was approved by the « Comité Régional d'Ethique pour
l'Expérimentation Animale du Languedoc-Roussillon ».
Statistical analysis
Data obtained in vitro are presented as mean ± SE of at
least three independent experiments performed in dupli-
cates. Analysis of in vivo experiments was done on 6 to 31
animals per treatment group. Data were analysed using
the Instat software (GraphPad Software, San Francisco,
CA). Statistical significance was set up at p < 0.05.
Results
Pretreatment with desipramine and fluoxetine prevent 
LPS-induced systemic inflammation and mortality in mice
The protective effect of desipramine and fluoxetine was
tested in a murine model of septic shock, in which endo-
toxemia and systemic inflammation is triggered by LPS
injection. Production of TNF-α is one of the earliest events
induced by LPS. Indeed, upon LPS treatment, concentra-
tion of TNF-α in the serum reached a peak after 90 min
and was back to basal level after 3 h (Fig. 1A and data not
shown). Therefore, mice were pretreated with the test
compound or saline 30 min before injection of LPS and
TNF-α concentration was measured 90 min afterwards.
Significant inhibition of TNF-α production occurred with
either drug at 5 mg/kg. This dose corresponds to the rec-
ommended daily dosage of desipramine in humans.
Because the inhibitory effect of prednisolone,
desipramine and fluoxetine was stronger at 10 or 20 mg/
kg, these doses were used in following experiments (Fig.
1B). We next analysed the survival of mice injected with
LPS and pretreated with 20 mg/kg of prednisolone,
desipramine or fluoxetine. These compounds notably
increased survival. The proportion of living mice rose
from 10% in the control group to 50% in the fluoxetine
group, and to 70% in the prednisolone and desipramine
groups (Fig. 2).
Effect of curative treatment with desipramine and 
fluoxetine on LPS-induced mortality in mice
Because severe sepsis is an acute inflammatory syndrome,
specific treatment in the clinic is initiated after symptomsRespiratory Research 2007, 8:35 http://respiratory-research.com/content/8/1/35
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have been declared. To mimic such curative treatment in
mice, repeated injections of antidepressants or pred-
nisolone were performed, starting 4 h after administration
of LPS, a time at which the first signs of sepsis such as diar-
rhoea, hypoactivity, piloerection, and shivering are appar-
ent. Prednisolone significantly increased the survival of
mice (40% survival versus 5% in the control group) (Fig.
3). Fluoxetine had no curative effect while desipramine
delayed time of death by few hours (Fig. 3). However, this
latter effect was not statistically significant.
Desipramine and fluoxetine inhibit release of TNF-α from 
freshly isolated human monocytes
Monocytes are the main source of TNF-α produced in the
blood stream during septic shock. Therefore, we next
tested whether desipramine and fluoxetine could act
directly on monocytes to inhibit LPS-induced TNF-α
release. After LPS treatment of human monocytes in pri-
mary cultures, concentration of TNF-α in supernatants
raised from 226 ± 16 pg/ml to 2848 ± 309 pg/ml (Fig. 4A).
As shown in Fig. 4B, desipramine and fluoxetine dose-
dependently inhibited TNF-α release.
Desipramine and fluoxetine reduce bronchial 
inflammation but not hyper responsiveness in ovalbumin-
sensitized rats
The anti-inflammatory effects of antidepressants were also
analysed in an animal model of allergic asthma. Brown
Norway rats were sensitized to ovalbumin to trigger bron-
chial hyperresponsiveness and airway inflammation. The
increase in bronchial responsiveness to metacholine
observed in sensitized rats was significantly reduced by
prednisolone but not by desipramine or fluoxetine (Fig.
5). Bronchoalveolar lavages of sensitized rats contained
an increased number of total inflammatory cells, which
was markedly inhibited by the three drugs (Fig. 6). Analy-
sis of leukocytes sub-populations revealed that pred-
nisolone and fluoxetine reduced the number of
macrophages (by 60% and 51%, respectively), lym-
phocytes (by 70% and 33%, respectively), neutrophils (by
72% and 38%, respectively) and eosinophils (by 97% and
60%, respectively), while desipramine diminished only
the number of macrophages (by 52%) and lymphocytes
(by 21%) (Fig. 7).
Desipramine and fluoxetine inhibit expression of RANTES 
in lung A549 epithelial cells
Accumulation of inflammatory cells in bronchoalveolar
lavages may result, at least in part, from an effect on lung
epithelial cells which have the capacity to produce chem-
okines. Thus, we examined the effect of desipramine and
fluoxetine on RANTES production in A549 lung epithelial
cells. After TNF-α treatment, concentration of RANTES in
cell culture supernatants raised from 7 ± 5 pg/ml to 2659
± 227 pg/ml (Fig. 8A). Antidepressants dose dependently
inhibited TNF-α-induced RANTES release. A maximal
inhibition of 50% was obtained at 10-5 M (Fig. 8B). TNF-
α-induced RANTES transcripts accumulation was also
Desipramine and fluoxetine inhibit release of TNF-α in serum of LPS- treated mice Figure 1
Desipramine and fluoxetine inhibit release of TNF-α in 
serum of LPS-treated mice. A, Mice (n = 12 per group) were 
injected with saline or LPS (50 mg/kg, i.p.). After 90 min, blood was 
collected and serum concentration of TNF-α was measured. Concen-
tration was 38 ± 12 pg/ml in saline and 4364 ± 265 pg/ml in LPS-
treated mice. *p < 0.0001 versus saline, by Welch t test. B, Mice (n = 
6–12 per group) were i.p. injected with saline or the indicated doses 
of desipramine, fluoxetine or prednisolone 30 min before administra-
tion of LPS. Blood was collected 90 min after LPS treatment, and 
serum concentration of TNF-α was measured. Data are shown as the 
percentage of LPS-induced TNF-α release. *p < 0.05 and **p < 0.001 
versus LPS alone, by ANOVA with Bonferroni post-test.
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decreased by approximately 50% after treatment by either
antidepressant (Fig. 8C).
Desipramine and fluoxetine repress NF-κB and AP-1 
activities
Because NF-κB and AP-1 play a crucial role in the expres-
sion and action of inflammatory mediators such as TNF-α
and RANTES, activity of these transcription factors was
measured in A549 cells treated by desipramine or fluoxe-
tine. Both antidepressants significantly repressed TNF-α-
induced NF-κB activity by about 40% (Fig. 9A).
Desipramine and fluoxetine decreased TPA-induced AP-1
activity by 30% and 25%, respectively (Fig. 9B).
Discussion
Central versus peripheral action
In the present study, desipramine and fluoxetine are
shown to affect the capacity of monocytes and lung epi-
thelial cells to produce inflammatory cytokines in vitro.
This observation favours a direct peripheral anti-inflam-
matory action of antidepressants. However, fluoxetine but
not the desipramine-related compound chlomipramine
has been shown to trigger anti-inflammatory effects
through the potentiation of serotoninergic transmission
ending up in activation of the pituitary-adrenocortical axis
[8,9]. Further evidence for a central mechanism was pro-
vided for bupropion-amfebutamone in a murine model
of severe sepsis. In this study, β-adrenergic and dopamin-
ergic receptor antagonists partially prevented bupropion
from reducing mortality rate [10]. To determine the rela-
tive contribution of central and peripheral action in the
anti-inflammatory effects, it would be interesting to mod-
ify antidepressant molecules so that they do not cross the
blood-brain barrier. If active, such molecules could
become prototypes for new anti-inflammatory drugs.
Molecular targets of antidepressants
The few previous reports investigating the effects of anti-
depressants on AP-1 and NF-κB were performed with
brain tissues or a neuronal cell line. Antidepressants were
found to regulate either positively or negatively DNA
binding activity of these transcription factors, depending
on the drug's chemical class, the brain region, and on
whether administration was acute or chronic [20-22]. We
report that desipramine and fluoxetine repress NF-κB and
AP-1 activities in a lung epithelial cell line. This may
Effect of a curative treatment with desipramine or fluoxetine  on LPS-induced mortality Figure 3
Effect of a curative treatment with desipramine or 
fluoxetine on LPS-induced mortality. Mice (n = 10–21 
per group) were treated with prednisolone (Pred, 20 mg/kg, 
i.p), desipramine (DMI, 20 mg/kg, i.p.), fluoxetine (Fluo, 20 
mg/kg, i.p.) or saline 4, 8, 12, 24, and 30 h after administra-
tion of LPS (50 mg/kg, i.p.) as indicated. Kaplan-Meier survival 
curves represent the percentage of surviving individuals in 
each groups. Mortality was evaluated daily (no additional 
death occurred after 96 h). *p = 0.0274 versus saline, by 
Fisher's exact test.
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Pretreatment with desipramine and fluoxetine prevents LPS- induced mortality Figure 2
Pretreatment with desipramine and fluoxetine pre-
vents LPS-induced mortality. Mice (n = 10–31 per 
group) were injected with saline, desipramine (DMI, 20 mg/
kg, i.p.), fluoxetine (Fluo, 20 mg/kg, i.p.) or prednisolone 
(Pred, 20 mg/kg, i.p.) as indicated 30 min before administra-
tion of LPS (50 mg/kg, i.p.). Kaplan-Meier survival curves rep-
resent the percentage of surviving individuals in each groups. 
Survival is shown over a 96 h period (no additional death 
occurred after 96 h). *p = 0.0129 and **p = 0.0005 versus 
saline, by Fisher's exact test.
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account for their anti-inflammatory effects in the animal
model of asthma as observed here. Indeed, AP-1 and NF-
κB have been involved in the pathogenesis of various
chronic inflammatory diseases, including asthma and
allergy [23,24]. In addition, NF-κB plays a key role in the
mortality of sepsis [25]. Thus, repression of NF-κB activity
by antidepressants may also explain their protective effect
in the model of septic shock. Concentrations of 1 to 10
μM were required to down-regulate AP-1 and NF-κB activ-
ities and expression of inflammatory cytokines. Such con-
centrations of antidepressants are reached in the plasma
[26,27], but are 10 to 1000 times higher than the dissoci-
ation constant of antidepressants for monoamine trans-
porters and receptors. Moreover, monoamine transporters
and receptors recognized by desipramine and fluoxetine
are not expressed in A549 cells as checked using oligonu-
cleotide microarrays (data not shown). Hence, antide-
pressants should exert their anti-inflammatory effects
through lower affinity receptors or effectors that remain to
be identified. Interestingly, fluoxetine at 5 to 15 μM was
shown to interfere with the activity of extrusion pumps
[28]. Similarly, desipramine at 10 μM was found to reduce
P-glycoprotein-like activity in vitro, thereby enhancing
glucocorticoid action [18]. As opposed to this latter study,
in our in vitro assays, antidepressants produced antiin-
flammatory effects in the complete absence of glucocorti-
coid. Moreover, A549 cells do not express P-glycoprotein
[29]. The effects of antidepressants in these cells are thus
not mediated through modulation of P-glycoprotein.
Desipramine and fluoxetine do not reduce bronchial hyper  responsiveness in sensitized rats Figure 5
Desipramine and fluoxetine do not reduce bronchial 
hyper responsiveness in sensitized rats. Unsensitized 
control rats (Cont) were nebulised with ovalbumin. Ovalbu-
min-sensitized rats were treated with saline (OVA+saline), 
prednisolone (OVA+Pred), desipramine (OVA+DMI) or 
fluoxetine (OVA+Fluo) at 10 mg/kg prior to nebulisation 
with ovalbumin. Rats (n = 6–7 per group) were then chal-
lenged with metacholine 24 h after ovalbumin nebulisation. 
Enhanced pause (Penh), which reflects airway obstruction, 
was measured by barometric plethysmography before (Pre-
Mch) and after (Post-Mch) the challenge. * p < 0.05 versus 
OVA+saline, by Student t test.
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Desipramine and fluoxetine inhibit release of TNF-α from  cultured monocytes Figure 4
Desipramine and fluoxetine inhibit release of TNF-α from 
cultured monocytes. A, Purified human monocytes were 
seeded at 100 000 cells per well and were left untreated (UT) or 
stimulated for 20 h with 100 ng/ml of LPS. Concentration of TNF-
α in supernatants was then measured. *p < 0.0001 versus 
untreated, by Welch t test. B, Cells were treated for 20 h with 
100 ng/ml of LPS in the presence of increasing concentrations of 
desipramine (DMI) or fluoxetine (Fluo). Data are shown as the 
percentage of LPS-induced TNF-α release. *p < 0.05 and **p < 
0.001 versus LPS alone, by ANOVA with Bonferroni post-test.
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Nevertheless, inhibition of drug efflux transporters in vivo
should increase concentration of endogenous glucocorti-
coids some in target cells and may account, at least partly,
for the anti-inflammatory properties of antidepressants.
Therapeutic effect of desipramine and fluoxetine in 
models of inflammatory diseases
The data presented herein demonstrate that desipramine
and fluoxetine have significant antiinflammatory proper-
ties in animal models of allergic asthma and septic shock.
Preventive treatment with desipramine and fluoxetine
markedly reduced TNF-α production and mortality in the
LPS-induced septic shock model. Desipramine provided
the same protection against mortality as the glucocorti-
coid prednisolone. However, it was less potent than pred-
nisolone in reducing TNF-α production. It is not
surprising that the inhibitory effect on TNF-α production
is not strictly correlated with survival rate since TNF-α is
not the sole mediator of lethality in severe sepsis [30].
Recently, another antidepressant, bupropion-amfebuta-
mone, was also shown to have a preventive therapeutic
effect in a murine model of severe sepsis [10]. In the same
model, we further show that antidepressants administered
curatively do not reduce final mortality rate, although
desipramine seem to delay time of death by few hours.
In the model of allergic asthma, antidepressants reduced
lung inflammation but not bronchial hyper responsive-
ness, whereas prednisolone was active on both aspects of
the pathology. Moreover, both antidepressants were not
as efficient as prednisolone in inhibiting inflammatory
cell counts. Thus, desipramine and fluoxetine exert
weaker or more restricted anti-inflammatory effects com-
pared to those of a glucocorticoid. Moreover, differences
were noted between the anti-inflammatory potencies of
desipramine and fluoxetine. Desipramine did not reduce
lung infiltration of neutrophils and eosinophils as
opposed to fluoxetine. Yet, in cultured lung epithelial
cells, both antidepressants inhibited with similar efficacy
the production of RANTES, a known chemotactic for eosi-
nophils. Possibly, expression of other eosinophils chem-
oattractants is affected by fluoxetine but not by
desipramine in the ovalbumin-sensitized rat model. Our
observation made in this model is also in apparent contra-
diction with data obtained by others showing an inhibi-
tion of neutrophils migration by tricyclic antidepressants
but not by fluoxetine [31]. However, in this latter study,
the migration experiments were performed with neu-
trophils in vitro. In vivo, antidepressants have a different
effect probably because they act on various additional cell
types such as T cells, macrophages, endothelial and epi-
thelial cells that affect the migration process.
Conclusion
The observation that antidepressants have anti-inflamma-
tory properties might have important clinical implica-
tions since these drugs are heavily prescribed worldwide
and chronic treatment often lasts several months. In
France alone, over 11 millions prescriptions for antide-
pressants were made during year 2000 [32]. Moreover,
there is a high prevalence of depression in patients with
asthma or other chronic inflammatory diseases
[12,13,33]. Thus, the anti-inflammatory effects of antide-
pressants should be considered especially in depressive
patients with inflammatory co-morbidity. In this regard,
tianeptine and citalopram, two antidepressants with yet
opposite action on serotonin re-uptake, were shown to
provide clinical benefit in asthma. In asthmatic children,
tianeptine reduces asthma symptoms and increases pul-
monary function [34], while in patients with asthma and
major depressive disorder, citalopram decreases systemic
glucocorticoid use, an important measure of severe
asthma exacerbations [35]. Tianeptine decreases free sero-
tonin plasma levels which are high in symptomatic
patients with asthma, and seems thus to act as a bron-
Desipramine and fluoxetine inhibit influx of inflammatory  cells in bronchoalveolar lavages of sensitized rats Figure 6
Desipramine and fluoxetine inhibit influx of inflam-
matory cells in bronchoalveolar lavages of sensitized 
rats. Ovalbumin-sensitized rats (OVA) treated with saline, 
prednisolone (Pred, 10 mg/kg), desipramine (DMI, 10 mg/kg) 
or fluoxetine (Fluo, 10 mg/kg) and control rats (Cont) (n = 
6–7 per group) were challenged with metacholine. Total 
number of inflammatory cells in bronchoalveolar lavages was 
then determined. *p < 0.01 and **p < 0.001 versus ovalbu-
min-sensitized rats treated with saline, by Student t test.
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chodilator. Obviously, another mechanism underlies the
anti-inflammatory properties of desipramine and fluoxet-
ine since these drugs do not reduce bronchial hyperre-
sponsiveness as shown herein. To ascertain the
significance of their anti-inflammatory effects in humans,
further clinical trials with antidepressants are required as
well as retrospective epidemiological studies assessing the
prevalence of inflammatory disorders, including septic
shock, in antidepressant-treated subjects.
Abbreviations
IκB, inhibitor of nuclear factor-κB; IKK, inhibitor of
nuclear factor-κB kinase; i.p., intraperitoneally; LPS,
lipopolysaccharides; NF-κB, nuclear factor-κB; OVA, oval-
Effects of desipramine and fluoxetine on leukocyte sub-populations in bronchoalveolar lavages of sensitized rats Figure 7
Effects of desipramine and fluoxetine on leukocyte sub-populations in bronchoalveolar lavages of sensitized 
rats. Ovalbumin-sensitized rats (OVA) treated with saline, prednisolone (Pred, 10 mg/kg), desipramine (DMI, 10 mg/kg) or 
fluoxetine (Fluo, 10 mg/kg) and control rats (Cont) (n = 6–7 per group) were challenged with metacholine. Cells in bronchoal-
veolar lavages were spun down on cytoslides, fixated and stained. Macrophages (panel A), lymphocytes (panel B), neutrophils 
(panel C) and eosinophils (panel D) were then counted under a microscope. A minimum of 200 cells was counted for each 
bronchoalveolar lavage. *p < 0.05 and **p < 0.001 versus ovalbumin-sensitized rats treated with saline, by Student t test.
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bumin; PBMC, peripheral blood mononuclear cells;
Penh, enhanced pause; RANTES, Regulated upon Activa-
tion, Normal T cell Expressed and presumably Secreted;
TNF-α, tumour necrosis factor-α; TPA, 12-O-tetrade-
canoyl-phorbol-13-acetate.
Desipramine and fluoxetine repress NF-κB and AP-1 activi- ties Figure 9
Desipramine and fluoxetine repress NF-κB and AP-1 
activities. A, A549 cells were transfected with a NF-κB luci-
ferase gene construct and pJ7-LacZ. After transfection, cells 
were either left untreated (UT) or pretreated or not for 1 h 
with desipramine (DMI, 10-5 M) or fluoxetine (Fluo, 10-5 M), 
and further stimulated for 4 h with TNF-α (10 ng/ml). NF-κB 
activity was normalised and that induced by TNF-α alone (47 
± 8 fold induction) was given the nominal value of 100 %. 
Data are shown as the percentage of activity relative to this 
nominal value. *p < 0.001 versus TNF-α alone, by Welch t 
test. B, A549 cells were transfected with an AP-1 luciferase 
gene construct and pJ7-LacZ. After transfection, cells were 
either left untreated (UT) or pretreated or not for 1 h as in 
A, and further stimulated for 4 h with TPA (10 ng/ml). AP-1 
activity was normalised and that induced by TPA alone (2.3 ± 
0.1 fold induction) was given the nominal value of 100 %. 
Data are shown as the percentage of activity relative to this 
nominal value. *p < 0.01 versus TPA alone, by Welch t test.
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Desipramine and fluoxetine inhibit RANTES expression Figure 8
Desipramine and fluoxetine inhibit RANTES expres-
sion. A, A549 cells were left untreated (UT) or stimulated 
for 20 h with TNF-α at 10 ng/ml. Concentration of RANTES 
in supernatants was then measured. *p < 0.0001 versus 
untreated, by Welch t test. B, A549 cells were stimulated for 
20 h with 10 ng/ml of TNF-α in the presence of increasing 
concentrations of desipramine or fluoxetine. Data are shown 
as the percentage of TNF-α-induced RANTES release. *p < 
0.05 versus TNF-α alone, by ANOVA with Bonferroni post-
test. C, A549 cells were either left untreated (UT) or pre-
treated or not for 1 h with desipramine (DMI) or fluoxetine 
(Fluo) at 10-5 M and further stimulated for 4 h with TNF-α at 
10 ng/ml. The amount of RANTES mRNA was quantified by a 
colorimetric assay. *p < 0.05 versus TNF-α alone, by Student 
t test.
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